Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Pipeline Review, H2 2018

  • ID: 4590313
  • Report
  • 54 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Bristol-Myers Squibb Co
  • Pfizer Inc
  • MORE
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Pipeline Review, H2 2018

Summary:

According to the recently published report 'Macrophage Stimulating Protein Receptor - Pipeline Review, H2 2018'; Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) pipeline Target constitutes close to 6 molecules.

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Macrophage-stimulating protein receptor is a protein encoded by the MST1R gene. It regulates many physiological processes including cell survival, migration and differentiation. Upon ligand binding at the cell surface it induces autophosphorylation of RON on its intracellular domain that provides docking sites for downstream signaling molecules and interacts with the PI3-kinase subunit PIK3R1, PLCG1.

The report 'Macrophage Stimulating Protein Receptor - Pipeline Review, H2 2018' outlays comprehensive information on the Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2 and 1 respectively.

Report covers products from therapy areas Oncology and Metabolic Disorders which include indications Gastric Cancer, Breast Cancer, Anaplastic Large Cell Lymphoma (ALCL), Anaplastic Thyroid Cancer, Bile Duct Cancer (Cholangiocarcinoma), Clear Cell Squamous Cell Carcinoma, Colon Cancer, Colorectal Cancer, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Lung Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Ovarian Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Multiple Myeloma (Kahler Disease), Neuroblastoma, Osteoporosis, Pancreatic Cancer, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Rhabdomyosarcoma and Uveal Melanoma.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1)
  • The report reviews Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bristol-Myers Squibb Co
  • Pfizer Inc
  • MORE
Introduction

Report Coverage

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Overview

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Companies Involved in Therapeutics Development

Advenchen Laboratories LLC

Aslan Pharmaceuticals Pte Ltd

Bristol-Myers Squibb Co

Lead Discovery Center GmbH

Pfizer Inc

SignalChem Lifesciences Corp

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Drug Profiles

AL-2846 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASLAN-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-777607 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

crizotinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RON Kinase for Pancreatic Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MST1R for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Dormant Products

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Discontinued Products

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Product Development Milestones

Featured News & Press Releases

Jun 11, 2018 : Pfizer’s Xalkori accepted for use in NHS Scotland

Jun 02, 2018 : Updated Phase 1 results of crizotinib against MET-amplified non-small cell lung cancer

May 29, 2018 : Pfizer's XALKORI (crizotinib) Receives FDA Breakthrough Therapy Designation in Two New Indications

Apr 15, 2018 : Crizotinib Yielded a High Objective Response Rate for Adult Patients With ALK-positive Inflammatory Myofibroblastic Tumor

Apr 02, 2018 : Lung cancer drug shows promise as targeted therapy for thousands with breast cancer

Feb 05, 2018 : Adding crizotinib to radiation therapy may help preserve hearing in patients with NF

Dec 08, 2017: Largest trial ever performed in alveolar soft part sarcoma: results published

Nov 14, 2017: XALKORI Approved by Health Canada for the Treatment of Patients with ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Sep 20, 2017: Publication of EORTC 90101 “CREATE” Phase II trial

Sep 11, 2017: Pfizer Presents Overall Survival Data of XALKORI in Patients With ALK-positive Advanced Non-small Cell Lung Cancer

Aug 30, 2017: New approach to genetic testing matches lung cancer patient with life-saving drug

Jun 02, 2017: OxOnc Announces that Co-development Partner Has Received Approval in Japan and Taiwan for Crizotinib (Xalkori) as a First-line Treatment for Patients with ROS1-Positive Non-Small Cell Lung Cancer

Feb 15, 2017: ASLAN Pharmaceuticals’ new ASLAN002 (BMS777607) phase 1 data published in Science Translational Medicine

Feb 03, 2017: AmoyDx ROS1 Fusion Test Kit was Approved by Japanese Authority as Companion Diagnostics for Pfizers Crizotinib

Jan 05, 2017: HTG Molecular Diagnostics Completes Module Three Filing for HTG EdgeSeq ALKPlus Assay PMA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Advenchen Laboratories LLC, H2 2018

Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2018

Pipeline by Bristol-Myers Squibb Co, H2 2018

Pipeline by Lead Discovery Center GmbH, H2 2018

Pipeline by Pfizer Inc, H2 2018

Pipeline by SignalChem Lifesciences Corp, H2 2018

Dormant Projects, H2 2018

Discontinued Products, H2 2018

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Advenchen Laboratories LLC
  • Aslan Pharmaceuticals Pte Ltd
  • Bristol-Myers Squibb Co
  • Lead Discovery Center GmbH
  • Pfizer Inc
  • SignalChem Lifesciences Corp
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll